Skip to content
Head to head

Belite Bio vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: BLTE · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

BLTE +9.0%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
BLTEVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price127.38515.02
Change today-15.65%-1.08%
1-year return+16.7%+22.0%
Market cap$5.17B$130.58B
52-week range115.41 – 200.00412.27 – 568.67
Valuation
P/E (TTM)-44.8533.14
P/E percentile, own 5-yr range40th99th
P/B6.716.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.3115.32
Net profit (TTM)$-93.82M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)--$3.20B
Provider cash-flow period date2025-12-302026-09-29
Ownership & sentiment
Institutional ownership66.2%96.8%
Insider activity (12mo)10 buy / 26 sell28 buy / 22 sell
Short interest (% of float)3.4%1.9%
Analyst consensus100% buy (6)95% buy / 5% hold (21)
Analyst price target$232 (+82%)$624 (+21%)
StockVane view
StockVane Quant RatingD (47)C (68)
Company
Employees416,400
Founded20181989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.